Fractionated stereotactic radiotherapy (FSRT) and stereotactic radiosurgery (SRS) are commonly used in patients with growth hormone (GH)-secreting pituitary adenomas (PAs) who are not candidates for surgery, have residual disease postoperatively, or have failed or cannot access medical therapy. The gene discussed is GH1; the disease is pituitary gland adenoma.